title: High dose melphalan for refractory myeloma--the M.D. Anderson experience.
authors.affiliation: University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Department of Hematology, Houston 77030.
authors.forename: B
authors.initials: B
authors.lastname: Barlogie
authors.forename: K A
authors.initials: KA
authors.lastname: Dicke
authors.forename: R
authors.initials: R
authors.lastname: Alexanian
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use*; D009101:Multiple Myeloma / Q000188:drug therapy*; D013781:Texas; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D014750:Vincristine; D003907:Dexamethasone; D008558:Melphalan